8-K: Revelation Biosciences Adjourns Special Stockholder Meeting

Revelation Biosciences, Inc. adjourned its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, due to a lack of quorum.

Summary

• Revelation Biosciences, Inc. (NASDAQ: REVB) announced the adjournment of its 2025 Special Meeting of Stockholders, originally convened on October 15, 2025.
• The meeting was adjourned because an insufficient number of shares were present to constitute a quorum, preventing a vote on the proposals.
• The Special Meeting will reconvene virtually on October 29, 2025, at 12:00 p.m., Eastern Time.
• The record date for the meeting, September 11, 2025, remains unchanged.
• Stockholders who have already voted do not need to take further action unless they wish to change their votes; those who have not yet voted are encouraged to do so.

Sentiment

Score: 4

Explanation: The adjournment of the Special Meeting due to a lack of quorum is a negative operational event, indicating insufficient shareholder engagement. However, the company has promptly rescheduled the meeting and is encouraging participation, which is a proactive step to resolve the issue.

Negatives

• The Special Meeting of Stockholders was adjourned due to a lack of quorum, indicating insufficient shareholder participation.

Risks

• Ability to meet financial and strategic goals due to competition.
• Ability to grow and manage growth profitably and retain key employees.
• Adverse effects from other economic, business, and/or competitive factors.
• Risks relating to the successful development of product candidates.
• Ability to successfully complete planned clinical studies of product candidates.
• Risk of not fully enrolling clinical studies or enrollment taking longer than expected.
• Risks relating to the occurrence of adverse safety events and/or unexpected concerns from clinical study data or analysis.
• Changes in applicable laws or regulations.
• Uncertainty regarding the timing of clinical data and the outcome of clinical studies, including whether results are positive or replicable.
• Uncertainty regarding the outcome of data collected and whether results and/or correlation can be replicated.
• Uncertainty regarding the timing, costs, conduct, and outcome of other clinical studies.
• Uncertainty regarding the anticipated treatment of future clinical data by regulatory authorities (FDA, EMA), including sufficiency for approval.
• Uncertainty regarding the success of future development activities for product candidates and potential indications.
• Ability to maintain the listing of securities on NASDAQ.
• Expected duration over which balances will fund operations.

Future Outlook

Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini, with multiple ongoing programs evaluating Gemini for post-surgical infection prevention, acute kidney injury prevention, and chronic kidney disease treatment. The company anticipates future clinical studies, data outcomes, and potential regulatory approvals, while acknowledging various risks inherent in drug development and operational sustainability.

Management Comments

• "The Company strongly encourages all stockholders, regardless of the number of shares they hold, to participate in the meeting and exercise their right to vote as soon as possible."

Industry Context

Revelation Biosciences operates within the highly competitive clinical-stage life sciences sector, focusing on inflammation-related therapies. The adjournment of a stockholder meeting due to a lack of quorum is a corporate governance event, not directly tied to broader industry trends, but highlights the importance of shareholder engagement common across all publicly traded companies in the sector.

Corporate Governance

Stakeholder Impact

• Shareholders are directly impacted by the delay in voting on proposals and are encouraged to actively participate in the reconvened meeting.
• The company faces potential operational delays if critical proposals requiring shareholder approval cannot be voted on in a timely manner.

Next Steps

• The Special Meeting of Stockholders will reconvene on October 29, 2025, at 12:00 p.m., Eastern Time, virtually via webcast.
• Stockholders who have not yet voted are encouraged to do so before the new meeting date.

Key Dates

Recommendation

The adjournment of the Special Meeting due to a lack of quorum is a governance concern, suggesting potential challenges in securing shareholder approval for proposals. While not a direct financial hit, it reflects on operational efficiency and shareholder engagement. However, the company has promptly rescheduled the meeting, providing an opportunity to resolve the issue. Investors should hold to see the outcome of the reconvened meeting and any subsequent disclosures, as the core business operations and financial health are not directly impacted by this specific event.

Keywords

Revelation Biosciences, REVB, Special Meeting, Stockholders, Adjournment, Quorum, Clinical-stage, Life Sciences, Corporate Governance, NASDAQ